Advertisement
AKBA vs SYRE
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a StrongBuy and SYRE is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AKBA’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).
- AKBA’s FA Score: 0 green, 5 red.
- SYRE’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AKBA’s TA Score shows that 3 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).
- AKBA’s TA Score: 3 bullish, 5 bearish.
- SYRE’s TA Score: 4 bullish, 3 bearish.
Price Growth
AKBA (@Biotechnology) experienced а -7.77% price change this week, while SYRE (@Biotechnology) price change was +9.21% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.
Reported Earning Dates
AKBA is expected to report earnings on Jul 31, 2025.
SYRE is expected to report earnings on Jul 31, 2025.
Industries' Descriptions
@Biotechnology (+7.60% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AKBA | SYRE | AKBA / SYRE | |
| Capitalization | 935M | 1.07B | 87% |
| EBITDA | 6.59M | -214.36M | -3% |
| Gain YTD | 87.368 | -23.582 | -370% |
| P/E Ratio | N/A | 1.68 | - |
| Revenue | 185M | 0 | - |
| Total Cash | 113M | 565M | 20% |
| Total Debt | 54.1M | 0 | - |
AKBA | SYRE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 59 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 38 | 54 | |
P/E GROWTH RATING 1..100 | 100 | 85 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYRE's Valuation (74) in the Pharmaceuticals Major industry is in the same range as AKBA (76) in the Biotechnology industry. This means that SYRE’s stock grew similarly to AKBA’s over the last 12 months.
SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to AKBA’s over the last 12 months.
SYRE's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to AKBA’s over the last 12 months.
AKBA's Price Growth Rating (38) in the Biotechnology industry is in the same range as SYRE (54) in the Pharmaceuticals Major industry. This means that AKBA’s stock grew similarly to SYRE’s over the last 12 months.
SYRE's P/E Growth Rating (85) in the Pharmaceuticals Major industry is in the same range as AKBA (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to AKBA’s over the last 12 months.
| AKBA | SYRE | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 81% | N/A |
| Stochastic ODDS (%) | 3 days ago 83% | 3 days ago 90% |
| Momentum ODDS (%) | 3 days ago 79% | 3 days ago 83% |
| MACD ODDS (%) | 3 days ago 90% | 3 days ago 85% |
| TrendWeek ODDS (%) | 3 days ago 86% | 3 days ago 84% |
| TrendMonth ODDS (%) | 3 days ago 85% | 3 days ago 84% |
| Advances ODDS (%) | 5 days ago 86% | 5 days ago 85% |
| Declines ODDS (%) | 3 days ago 85% | 17 days ago 89% |
| BollingerBands ODDS (%) | 3 days ago 90% | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 89% | N/A |
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RYMGX | 52.08 | 0.87 | +1.70% |
| Rydex S&P MidCap 400 Pure Growth A | |||
| FDGKX | 42.54 | 0.21 | +0.50% |
| Fidelity Dividend Growth K | |||
| NRAEX | 52.61 | 0.22 | +0.42% |
| Neuberger Berman Sustainable Equity E | |||
| DALCX | 27.33 | 0.11 | +0.40% |
| Dean Mid Cap Value | |||
| ERBCX | 19.29 | 0.05 | +0.26% |
| Eaton Vance RBA Equity Strategy Fd Cl C | |||
AKBA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with IPSC. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then IPSC could also see price increases.
| Ticker / NAME | Correlation To AKBA | 1D Price Change % | ||
|---|---|---|---|---|
| AKBA | 100% | -7.29% | ||
| IPSC - AKBA | 39% Loosely correlated | -5.17% | ||
| XERS - AKBA | 39% Loosely correlated | -2.90% | ||
| ADAP - AKBA | 39% Loosely correlated | +19.62% | ||
| ATOS - AKBA | 37% Loosely correlated | -2.55% | ||
| SYRE - AKBA | 37% Loosely correlated | +1.08% | ||
More | ||||
SYRE and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.
| Ticker / NAME | Correlation To SYRE | 1D Price Change % | ||
|---|---|---|---|---|
| SYRE | 100% | +1.08% | ||
| IDYA - SYRE | 60% Loosely correlated | -1.33% | ||
| BEAM - SYRE | 58% Loosely correlated | +3.68% | ||
| CGON - SYRE | 57% Loosely correlated | -0.15% | ||
| XNCR - SYRE | 57% Loosely correlated | N/A | ||
| KRYS - SYRE | 54% Loosely correlated | -1.59% | ||
More | ||||